News for Plus Therapeutics, Inc. (PSTV)

Plus Therapeutics (PSTV) has announced the receipt of a $1.6 million advance payment, which forms part of a larger $17.6 million grant awarded by the Cancer Pre

Summary: Plus Therapeutics secures a $1.6 million advance from a substantial grant, enhancing its financial standing. Analysts predict a significant upsi

Plus Therapeutics (PSTV) receives a $1.6 million advance from CPRIT as part of a $17.6 million grant. The funding supports the development of REYOBIQâ„¢

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system met

Primary objective to determine optimal dosing schedule for a registrational trial

In recent analyst coverage, Plus Therapeutics (PSTV) remains on the radar as HC Wainwright & Co. continues its

H.C. Wainwright's analyst, Sean Lee, has revised the price target for Plus Therapeutics (PSTV), reducing it from $5.50 to $3. Despite the adjustment, the analys

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Wednesday. The Dow traded down 0.18% to 43,011.70 while the NA...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 50 points on Wednesday. Following the market opening Wednesday, the Dow trad...

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.2% on Wednesday. The Dow traded up 0.26% to 42,324.65 while the NASDAQ r...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.36% to 42,366.99 while ...

Summary: Plus Therapeutics (PSTV) has initiated a prospectus involving up to 17 million shares. The company could potentially receive $50 million from a

Plus Therapeutics, identified by the stock ticker PSTV, has recently submitted a filing for the sale of 17 million shares of common stock. This development is s

Stock News● Sanofi (SNY) announced its acquisition of Blueprint Medicines for approximately $9.1 billion, or $129.00 per share in cash. The deal, expected to

Plus Therapeutics (PSTV) Q1 results missed expectations with significant EPS and revenue declines. Cash reserves increased to $9.9 million, providing a

Company continues to progress both REYOBIQâ„¢ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE

In the first quarter of 2025, Plus Therapeutics (PSTV) recognized $1.1 million in grant revenue, a decrease from the $1.7 million recorded during the same perio

HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. ( PSTV) (the ”œCompany”) today announced it received a delinquency notification letter fr